Skip to main content
SpringerLink
Log in

The Cost of HIV Treatment and Care

A Global Review

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

This review of published studies on the costs of HIV treatment and care describes some of the recent developments that have influenced these costs in industrialised and industrialising countries, especially within the context of changing drug treatments. Some of the different approaches to estimating the economic impact of HIV infection are briefly presented. The methods used to review the literature are described, particularly the criteria of a scoring system that was specifically developed to systematically screen some of the studies identified. The mean review score for studies dealing with direct hospital costs increased significantly (p = 0.003) over the 3 periods analysed (before 1987, 1987 to 1995, and 1996 and beyond), indicating that the overall ‘quality’ of studies increased over time.

All cost estimates, other than those from non-industrialised regions, were converted to 1996 US dollars using country-specific total health expenditure inflaters and country-specific Gross Domestic Product Purchasing Power Parity converters. A summary of hospital cost estimates over time and by region demonstrated that the costs of treating asymptomatic individuals and people with symptomatic non-AIDS increased over the period, but that the costs of treating individuals with AIDS appears to have stabilised since the late 1980s. As fewer studies could be identified on the costs of community and informal care, indirect productivity costs and population cost estimates, and costs of care for children with HIV infection, all of these studies were reviewed without the use of the scoring system.

Finally, the discussion explores the evidence on the global costs of HIV in non-industrialised economies and the affordability of HIV treatment and care. Some suggestions for the direction of future HIV costing studies are also presented. A need remains for good quality cost data. Adequate research effort should be directed to improving the scope and quality of information on costs of HIV service provision around the world.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997

    Google Scholar 

  2. Scitovsky AA. Studying the cost of HIV-related illnesses: reflections on the moving target. Milbank Q 1989; 67: 318–44

    Article  PubMed  CAS  Google Scholar 

  3. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA 1999; 281: 2305–15

    Article  PubMed  CAS  Google Scholar 

  4. Centers for Disease Control. Pneumocystis pneumonia. MMWR Morb Mortal Wkly Rep 1981; 30: 250

    Google Scholar 

  5. Centers for Disease Control. Kaposi’s sarcoma. MMWR Morb Mortal Wkly Rep 1981; 30: 305–8

    Google Scholar 

  6. UNAIDS. AIDS epidemic update. Joint United Nations Programme on AIDS. Geneva: World Health Organization, 1999

    Google Scholar 

  7. Merson M. HIV infection: the global perspective. J Acquir Immune Defic Syndr 1991; 4: 305

    Google Scholar 

  8. Mann JM, Chin J. AIDS: a global perspective. N Engl J Med 1988; 319: 302–3

    Article  PubMed  CAS  Google Scholar 

  9. Pepin J, Plummer FA, Brunham RC, et al. The interaction of HIV infection and other sexually transmitted diseases: an opportunity for intervention. AIDS 1989; 3: 3–9

    PubMed  CAS  Google Scholar 

  10. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41: 1–19

    Google Scholar 

  11. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes on HIV-1 infection. Nature 1995; 373: 123–6

    Article  PubMed  CAS  Google Scholar 

  12. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117–22

    Article  PubMed  CAS  Google Scholar 

  13. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  14. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10 Suppl. 3: S1–11

    PubMed  CAS  Google Scholar 

  15. Delta Co-ordinating Committee. Delta: a randomised double blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283–91

    Article  Google Scholar 

  16. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1996; 335: 1099–106

    Article  PubMed  CAS  Google Scholar 

  17. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188–91

    Article  PubMed  CAS  Google Scholar 

  18. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998; 352: 314–6

    Article  PubMed  CAS  Google Scholar 

  19. Beck EJ, Mandalia S, Parmer D, et al., NPMS Steering Group. Reduced HIV disease progression and mortality due to combination antiretroviral therapy in English NPMS-HHC clinics [poster TuPeC3331]. 13th International AIDS Conference; 2000 Jul 11; Durban

    Google Scholar 

  20. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society — USA Panel. JAMA 1997; 277: 1962–9

    Article  PubMed  CAS  Google Scholar 

  21. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society — USA Panel. JAMA 1998; 280: 78–86

    Article  PubMed  CAS  Google Scholar 

  22. Curtis H. Funding implications of combination therapies. J Comb Ther 1997; 2: 27–8

    Google Scholar 

  23. Bloom DE, River Path Association. Something to be done: treating HIV/AIDS. Science 2000; 288: 2171–3

    Article  PubMed  CAS  Google Scholar 

  24. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982; 96: 102–9

    PubMed  CAS  Google Scholar 

  25. Beck EJ, Beecham J, Mandalia S, et al. What is the cost of getting the price wrong? J Public Health Med 1999; 21: 311–7

    Article  PubMed  CAS  Google Scholar 

  26. Rees M. Report on the HIV/AIDS costing ‘revisit’. London: Department of Economics, University of Buckingham, 1995

    Google Scholar 

  27. Wright KG, Haycox A. Public sector costs of caring for mentally handicapped persons in a large hospital. Discussion paper no. 1. York: Centre for Health Economics, University of York, 1984

    Google Scholar 

  28. Tolley K, Gyldmark M. The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe. Health Policy 1993; 24: 55–70

    Article  PubMed  CAS  Google Scholar 

  29. Knapp M. Background theory. In: Netten A, Beecham J, editors. Costing community care: theory & practice. Aldershot: Ashgate Publishing Ltd, 1993

    Google Scholar 

  30. Knapp M, Beecham J, Renshaw J. The cost-effectiveness of psychiatric provision services. Personal Social Services Research Unit discussion paper 533/2. Kent: University of Kent, 1987

    Google Scholar 

  31. The World Bank. World Bank development report 1998/99: knowledge for development. New York (NY): Oxford University Press, 1999

    Google Scholar 

  32. Hiatt RA, Quesenberry CPJ, Selby JV, et al. The cost of acquired immunodeficiency syndrome in northern California. The experience of a large prepaid health plan. Arch Intern Med 1990; 150: 833–8

    Article  PubMed  CAS  Google Scholar 

  33. Solomon DJ, Hogan AJ, Bouknight RR, et al. Analysis of Michigan Medicaid costs to treat HIV infection. Public Health Rep 1989; 104: 416–24

    PubMed  CAS  Google Scholar 

  34. Andrews RM, Keyes MA, Fanning TR, et al. Lifetime medical service utilization and expenditures for AIDS in New York and California. J Acquirr Immune Defic Syndr 1991; 4: 1046–58

    CAS  Google Scholar 

  35. Moss NE, Kahn JG, Benjamin AE, et al. Medical care utilization and associated charges for patients with symptomatic HIV disease. AIDS Public Policy J 1991; 6: 125–9

    Google Scholar 

  36. Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre, 1983–1989. AIDS 1994; 8: 367–77

    Article  PubMed  CAS  Google Scholar 

  37. Whyte BM, Evans DB, Schreurs EJ, et al. The costs of hospital-based medical care for patients with the acquired immunodeficiency syndrome. Med J Austr 1987; 147: 269–72

    CAS  Google Scholar 

  38. Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquir Immune Defic Syndr 1990; 3: 904–12

    PubMed  CAS  Google Scholar 

  39. Seage III GR, Landers S, Lamb GA, et al. Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health 1990; 80: 835–9

    Article  PubMed  Google Scholar 

  40. Bennett CL, Cvitanic M, Pascal A. The costs of AIDS in Los Angeles. J Acquir Immune Defic Syndr 1991; 4: 197–203

    Article  PubMed  CAS  Google Scholar 

  41. Andrulis DP, Weslowski VB, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992; 267: 2482–6

    Article  PubMed  CAS  Google Scholar 

  42. Bennett C, Pascal A, Cvitanic M, et al. Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immune Defic Syndr 1992; 5: 1–6

    PubMed  CAS  Google Scholar 

  43. Rietmeijer CA, Davidson AJ, Foster CT, et al. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. Arch Intern Med 1993; 153: 219–25

    Article  PubMed  CAS  Google Scholar 

  44. Hellinger FJ, Fleishman JA, Hsia DC. AIDS treatment costs during the last months of life: evidence from the ACSUS. Health Serv Res 1994; 29: 569–81

    PubMed  CAS  Google Scholar 

  45. Epstein AM, Seage G, Weissman JS, et al. Costs of medical care and out-of-pocket expenditures for persons with AIDS in the Boston Health Study. Inquiry 1995; 32: 211–21

    PubMed  CAS  Google Scholar 

  46. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 223–31

    Article  PubMed  CAS  Google Scholar 

  47. Perdue EB, Weidle PJ, Everson-Mays RE, et al. Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 354–60

    Article  PubMed  CAS  Google Scholar 

  48. Abou-Sayf FK, Marzolf JR. Medical care costs of patients with AIDS in Hawaii. Hawaii Med J 1989; 48: 194–9

    PubMed  CAS  Google Scholar 

  49. Beck EJ, Whitaker L, Kennelly J, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS 1994; 8: 379–84

    Article  PubMed  CAS  Google Scholar 

  50. Kennelly JM, Tolley KH, Ghani AC, et al. Hospital costs of treating haemophilic patients infected with HIV. AIDS 1995; 9: 787–93

    Article  PubMed  CAS  Google Scholar 

  51. Nageswaran A, Kinghorn GR, Shen RN, et al. Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department. Int J STD AIDS 1995; 6: 336–44

    PubMed  CAS  Google Scholar 

  52. Beck EJ, Kupek EJ, Petrou S, et al. Survival and the use and costs of hospital services for London AIDS patients treated with AZT. Int J STD AIDS 1996; 7: 507–12

    Article  PubMed  CAS  Google Scholar 

  53. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997; 12 (1): 54–66

    Article  PubMed  CAS  Google Scholar 

  54. Brettle RP, Atkinson FI, Wilcock J, et al. The cost of health care for HIV-positive patients. Int J STD AIDS 1997; 8: 50–3

    Article  PubMed  CAS  Google Scholar 

  55. Beck EJ, Kupek EJ, Wadsworth J, et al. The use and cost of hospital services by London AIDS patients with different AIDS defining conditions. J Public Health Med 1996; 18: 457–64

    Article  PubMed  CAS  Google Scholar 

  56. Borleffs JC, Jager JC, Poos MJ, et al. Hospital cost for patients with HIV infection in a University Hospital in the Netherlands. Health Policy 1990; 16 (1): 43–54

    Article  PubMed  CAS  Google Scholar 

  57. Hurley SF, Kaldor JM, Carlin JB, et al. The usage and costs of health services for HIV infection in Australia. AIDS 1995; 9: 777–85

    Article  PubMed  CAS  Google Scholar 

  58. Peyron F, Flori A, Galliano-di Bernardo Bernardo S, et al. Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Pharm World Sci 1997; 19 (4): 202–7

    Article  PubMed  CAS  Google Scholar 

  59. McDermott J, Williamson E, Wallace E, et al. Hospital outpatient costs for patients with HIV infection. N Z Med J 1991; 104: 43–4

    PubMed  CAS  Google Scholar 

  60. Dijkgraaf MG, Luijben AH, Jager JC, et al. In-patient care for symptomatic, HIV-infected persons: a longitudinal study of hospitalizations, in-patient drug use, and related costs. AIDS Care 1995; 7: 321–36

    Article  PubMed  CAS  Google Scholar 

  61. De Graeve D, Lescrauwaet B, Nonneman W. Patient classification and cost analysis of AIDS and HIV: the case of Belgium. Health Policy 1997; 39: 93–106

    Article  PubMed  Google Scholar 

  62. Beck EJ, Tolley K. Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy. Int J STD AIDS 1998; 9: 512–7

    Article  PubMed  CAS  Google Scholar 

  63. Beck EJ, Tolley K, Power A, et al. The use and cost of HIV service provision in England in 1996. Pharmacoeconomics 1998; 14 (6): 639–52

    Article  PubMed  CAS  Google Scholar 

  64. Beck EJ, Pozniak A, Molesworth A, et al. Changing cost of English HIV service provision, 1996–1997. Int J STD AIDS 1999; 10: 357–62

    Article  Google Scholar 

  65. Okello DO. Resource utilization patterns in patients with acquired immunodeficiency syndrome (AIDS). East Afr Med J 1994; 71: 816–7

    PubMed  CAS  Google Scholar 

  66. Berger R. Cost analysis of AIDS cases in Maryland. Md Med J 1985; 34: 1173–5

    PubMed  CAS  Google Scholar 

  67. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986; 256: 3103–6

    Article  PubMed  CAS  Google Scholar 

  68. Kaplowitz LG, Turshen IJ, Myers PS, et al. Medical care costs of patients with acquired immunodeficiency syndrome in Richmond, Va. A quantitative analysis. Arch Intern Med 1988; 148: 1793–7

    Article  PubMed  CAS  Google Scholar 

  69. Kelly JV, Ball JK, Turner BJ. Duration and costs of AIDS hospitalizations in New York. Variations by patient severity of illness and hospital type. Med Care 1989; 27: 1085–98

    Article  PubMed  CAS  Google Scholar 

  70. Seage GR, Landers S, Barry A, et al. Medical care costs of AIDS in Massachusetts. JAMA 1986; 256: 3107–9

    Article  PubMed  Google Scholar 

  71. Johnson AM, Adler MW, Crown JM. The acquired immune deficiency syndrome and epidemic of infection with human immunodeficiency virus: costs of care and prevention in an inner London district. Br Med J (Clin Res Ed) 1986; 293: 489–92

    Article  CAS  Google Scholar 

  72. Bjornson DC, Oster CN, Hiner Jr WO, et al. The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population. DICP 1991; 25 (4): 414–7

    PubMed  CAS  Google Scholar 

  73. Chupka LA, Birden HH, Andrews L. Financial aspects of the provision of care to AIDS patients at Hartford Hospital. Conn Med 1992; 56: 467–8

    PubMed  CAS  Google Scholar 

  74. Weiss PJ, Kennedy CA, Wallace MR, et al. Medication costs associated with the care of HIV-infected patients. Clin Ther 1993; 15: 912–6

    PubMed  CAS  Google Scholar 

  75. Allison-Cooke S. The pattern and cost of hospital care for persons with HIV/AIDS in Guilford County, NC, 1987–1991. N C Med J 1994; 55 (4): 131–4

    PubMed  CAS  Google Scholar 

  76. Rosenblum LS, Castro KG, Dooley S, et al. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. Ann Intern Med 1994; 121: 786–92

    PubMed  CAS  Google Scholar 

  77. Andrulis DP, McGregor CM, Weiss KB, et al. U.S. hospital care for HIV-infected persons and the role of public and private teaching hospitals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 193–203

    PubMed  CAS  Google Scholar 

  78. Fleishman JA, Mor V, Laliberte LL. Longitudinal patterns of medical service use and costs among people with AIDS. Health Serv Res 1995; 30: 403–24

    Google Scholar 

  79. Rüttimann S, Tschudi M, Dubach UC. Medical care cost of ambulatory patients infected with the human immunodeficiency virus: analysis at a Swiss outpatient clinic. Eur J Intern Med 1992; 3: 141–6

    Google Scholar 

  80. Swaden L, Sabin CA, Phillips AN. CD4 lymphocyte count as a predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs. Int J Pharm Pract 1992; 1: 210–1

    Article  Google Scholar 

  81. Carlsson R, Dickson N, McDermott J, et al. Hospital associated costs of treating patients with AIDS. N Z Med J 1993; 106: 76–8

    Google Scholar 

  82. Morton A, McCallum AK, Parkin DW, et al. The patient profile approach to assessing the cost of AIDS and HIV infection. J Publ Health Med 1993; 15: 235–42

    CAS  Google Scholar 

  83. Peter DL, McDougall M, Maartens G, et al. The cost of adult AIDS inpatient care. S Afr Med J 1994; 84: 447–8

    PubMed  CAS  Google Scholar 

  84. Jebakumar SP, Woolley PD, Curless E. Lifetime cost of treating a person with HIV infection. Int J STD AIDS 1995; 6: 444–6

    PubMed  CAS  Google Scholar 

  85. Anis AH, Hogg RS, Yip B, et al. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women. Pharmacoeconomics 1998; 13 (3): 327–36

    Article  PubMed  CAS  Google Scholar 

  86. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963–9

    Article  PubMed  CAS  Google Scholar 

  87. Organization for Economic Co-operation and Development (OECD)/CREDES. OECD health data 99: a comparative analysis of 29 countries [CD-ROM]. Paris: OECD/CREDES, 1999

    Google Scholar 

  88. Ward D, Brown MA. Labor and cost in AIDS family caregiving. West J Nurs Res 1994; 16: 10–22

    Article  PubMed  CAS  Google Scholar 

  89. Bowie RD, Tobias MI, Williams T. The private costs of HIV/ AIDS. N Z Med J 1996; 109: 51–4

    PubMed  CAS  Google Scholar 

  90. Petrou S, Dooley M, Whitaker L, et al. Cost and utilisation of community services for people with HIV infection in London. Health Trends 1995; 27: 62–8

    PubMed  CAS  Google Scholar 

  91. Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmacoeconomics 1996; 9(4): 332–40

    Article  PubMed  CAS  Google Scholar 

  92. Hansen K, Woelk G, Jackson H, et al. The cost of home-based care for HIV/AIDS patients in Zimbabwe. AIDS Care 1998; 10: 751–9

    Article  PubMed  CAS  Google Scholar 

  93. Hardy AM, Rauch K, Echenberg D. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986; 255: 209–11

    Article  PubMed  CAS  Google Scholar 

  94. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. J Med Pract Manage 1988; 3: 234–41

    PubMed  CAS  Google Scholar 

  95. Begley CE, Crane MM, Perdue G. Estimating themortality cost of AIDS: do estimates of earnings differ? Am J Public Health 1990; 80: 1268–70

    Article  PubMed  CAS  Google Scholar 

  96. Seidman RL, Williams SJ, Mortensen LM. Assessing the economic impact of AIDS in local communities. Current and projected costs for San Diego County. West J Med 1989; 151: 467–71

    PubMed  CAS  Google Scholar 

  97. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339: 1897–904

    Article  PubMed  CAS  Google Scholar 

  98. Herlitz C, Brorsson B. The AIDS epidemic in Sweden: estimates of costs, 1986, 1987 and 1990. Scand J Soc Med 1989; 17: 39–48

    PubMed  CAS  Google Scholar 

  99. Postma MJ, Leidl R, Downs AM, et al. Economic impact of the AIDS epidemic in the European Community: towards multinational scenarios on hospital care and costs. AIDS 1993; 7: 541–53

    Article  PubMed  CAS  Google Scholar 

  100. Pandav CS, Anand K, Shamanna BR, et al. Economic consequences of HIV/AIDS in India. Natl Med J India 1997; 10: 27–30

    PubMed  CAS  Google Scholar 

  101. Konde-Lule JK, Sebina AJ. The impact of AIDS in a rural Ugandan community. East Afr Med J 1993; 70: 725–9

    PubMed  CAS  Google Scholar 

  102. Farnham PG, Gorsky RD. Costs to business for an HIV-infected worker. Inquiry 1994; 31: 76–88

    PubMed  CAS  Google Scholar 

  103. Leigh JP, Lubeck DP, Farnham P, et al. Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 392–8

    Article  PubMed  CAS  Google Scholar 

  104. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use in hospital services in English HIV infected individuals with increased uptake of anti-retroviral therapy 1996–1997. AIDS 2000; 13: 2157–64

    Article  Google Scholar 

  105. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89

    Article  PubMed  CAS  Google Scholar 

  106. Hegarty JD, Abrams EJ, Hutchinson VE, et al. The medical care cost of human immunodeficiency virus-infected children in Harlem. JAMA 1988; 260: 1901–5

    Article  PubMed  CAS  Google Scholar 

  107. Conviser R, Grant CM, Coye MJ. Pediatric acquired immunodeficiency syndrome hospitilizations in New Jersey. Pediatrics 1991; 87: 642–53

    PubMed  CAS  Google Scholar 

  108. Muller C, Fahs MC, Mulak G, et al. Pediatric AIDS at Mount Sinai Medical Center 1988-89: a study of costs and social severity. Soc Work Health Care 1996; 22: 1–20

    Article  PubMed  CAS  Google Scholar 

  109. Hsia DC, Fleishman JA, East JA, et al. Pediatric human immunodeficiency virus infection: recent evidence on the utilization and costs of health services. Arch Pediatr Adolesc Med 1995; 149: 489–96

    Article  PubMed  CAS  Google Scholar 

  110. Havens PL, Cuene BE, Holtgrave DR. Lifetime cost of care for children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997; 16: 607–10

    Article  PubMed  CAS  Google Scholar 

  111. Carlin JB, Langdon P, Hurley SF, et al. Health care and its costs for children with perinatally acquired HIV infection. J Paediatr Child Health 1996; 32: 42–7

    Article  PubMed  CAS  Google Scholar 

  112. Beck EJ, Mandalia S, Griffith R, et al. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre. Pharmacoeconomics 2000; 17 (1): 53–69

    Article  PubMed  CAS  Google Scholar 

  113. Nelson E, Weikert M, Phillips JA. Paediatric treatment costs and the HIV epidemic. Cent Afr J Med 1995; 41: 139–44

    PubMed  CAS  Google Scholar 

  114. Youle M, Trueman P, Simpson K, et al. Health economics in HIV disease: a review of the European literature. Pharmacoeconomics 1999; 15 Suppl. 1: 1–12

    Article  PubMed  Google Scholar 

  115. Hogg RS, O’shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997; 349: 1294

    Article  PubMed  CAS  Google Scholar 

  116. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101–5

    Article  PubMed  CAS  Google Scholar 

  117. Wurst J. Health Africa: UN Security Council, breaking tradition, takes up AIDS. Inter Press Service [online]. Available from: URL: http://www.aegis.com/news/ips/2000/IP000105.html2000 [Accessed 2000 Aug 30]

    Google Scholar 

  118. Beck EJ, Miners AH. Assessing HIV service provision: why costs are also important. In: Miles A, editor. The effective management of HIV disease. London: Aesculapius Medical Press. In press

  119. Direction des Hospitaux, M.S. DMI2: an information system built around the patient. INSERIM — SC4. Paris: Ministere de la Sante et de l’action Humanitaire, 1993

    Google Scholar 

  120. Beck EJ. Counting the cost of HIV service provision in England: where do we go from here? J HIV Comb Ther 1997; 2: 29–32

    Google Scholar 

Download references

Acknowledgements

Keith Tolley was located at Nottingham University when this work was first undertaken, but is currently Senior Health Economist at Glaxo Wellcome UK.

Author information

Authors and Affiliations

  1. Joint Departments of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, H3A 1A2, Québec, Canada

    Eduard J. Beck

  2. NPMS-HHC CAC, St Stephen’s Centre, Chelsea & Westminster Hospital, London, England

    Eduard J. Beck & Alec H. Miners

  3. Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, England

    Alec H. Miners

  4. Department of Economics, University of Nottingham, Nottingham, England

    Keith Tolley

Authors
  1. Eduard J. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alec H. Miners
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith Tolley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduard J. Beck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beck, E.J., Miners, A.H. & Tolley, K. The Cost of HIV Treatment and Care. Pharmacoeconomics 19, 13–39 (2001). https://doi.org/10.2165/00019053-200119010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119010-00002

Keywords

Search

Navigation